- Home
- WIW vs EBS Comparison
WIW vs EBS Comparison
Compare WIW & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WIW | EBS |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 540.9M | 625.0M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | WIW | EBS |
|---|---|---|
| Price | $8.71 | $11.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 229.9K | ★ 821.3K |
| Earning Date | 01-01-0001 | 10-29-2025 |
| Dividend Yield | ★ 11.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.35 |
| Revenue | N/A | ★ $788,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.21 |
| P/E Ratio | ★ N/A | $8.75 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.01 | $4.02 |
| 52 Week High | $9.37 | $13.41 |
Technical Indicators
Market Signals| Indicator | WIW | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 41.09 | 62.78 |
| Support Level | $8.69 | $11.65 |
| Resistance Level | $8.87 | $12.28 |
| Average True Range (ATR) | 0.07 | 0.59 |
| MACD | -0.00 | 0.12 |
| Stochastic Oscillator | 34.69 | 88.96 |
Price Performance
Historical ComparisonAbout WIW Western Asset Inflation-Linked Opportunities & Income Fund
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. Its primary investment objective of the group is to provide current income for its shareholders. The secondary investment objective is capital appreciation with current income.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.